Cancer immunotherapy.
The immune system is generally divided into 2 primary components: the innate immune response, and the highly specific but more slowly developing adaptive or acquired immune response. Immune responses can be further separated by whether they are induced by exposure to a foreign antigen (an "active" response) or whether they are transferred through serum or lymphocytes from an immunized individual (a "passive" response). The ideal cancer immunotherapy agent should be able to discriminate between cancer and normal cells (ie, specificity), be potent enough to kill small or large numbers of tumor cells (ie, sensitivity), and lastly be able to prevent recurrence of the tumor (ie, durability). Tumor immunology and immunotherapy is one of the most exciting and rapidly expanding fields at present.
Bergman
Philip J
PJ
BrightHeart Veterinary Centers Armonk, NY, USA. pbergman@brightheartvet.com
D000818:Animals; D002371:Cat Diseases / Q000276:immunology* / Q000628:therapy*; D002415:Cats; D004283:Dog Diseases / Q000276:immunology* / Q000628:therapy*; D004285:Dogs; D007167:Immunotherapy / Q000379:methods / Q000662:veterinary*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy* / Q000662:veterinary*